FindTrial
Sign In

a Study of EGFR & ALK Test in Lung cancer patients.

Clinical and Epidemiological Study of EGFR Mutation and EML4-ALK Fusion Gene among Indian Patients with Adenocarcinoma Lung

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/10/010086
Enrollment
500
Registered
2017-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Lung Cancer Patients

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Specimens with adequate tumor burden ( >50% of tumors cells) will taken for the FISH analysis. The assessment will be done by a pathologist on the H&E.

Exclusion criteria

Exclusion criteria: No Exclusion criteria as the study is to be done only on the Tumor tissue blocks.

Design outcomes

Primary

MeasureTime frame
The Specific aims of the proposed study are to conduct a large-scale study among Lung Cancer patients in India to a) Estimate the prevalence of EGFR and EML4-ALK fusion in Indian NSCLC (adenocarcinoma) patient population; b) Evaluate the association of EGFR and EML4-ALK fusion with clinical and pathologic parameters of NSCLC (adenocarcinoma) and patient characteristics; Timepoint: End of the study—

Secondary

MeasureTime frame
Not applicableTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactDr Kumar Prabhash

Tata Memorial hospital

kprabhash1@gmail.com09167760576

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026